ReviewFrontiers in pharmacology2023
Astragaloside IV, as a potential anticancer agent.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular mechanisms of astragaloside-IV in hepatocellular carcinoma therapy: a systematic review.BMC cancer · 2025Pooled it
- Protective effects of Astragaloside IV on various liver diseases: From chemistry to herbal medicines (Review).International journal of molecular medicine · 2026Review
- Review
- Astragaloside IV targets TUBB4B to inhibit proliferation and promote apoptosis of pituitary tumor cells via the STMN1/ERK pathway.International journal of molecular medicine · 2026Article
- Biomimetic Cell Membrane-Coated MOFs System for Targeted Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Mechanism of Astragaloside IV Against Cerebral Ischemia-Reperfusion Injury: Inhibiting Neuronal Apoptosis via the CytC/Apaf-1 Mitochondrial Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The Multitalented Marvels: Exploring the Versatile Potential of Natural Products in Osteosarcoma Treatment.Cancer informatics · 2026Review
- Programmable saponin biosynthesis from gene networks to predictive biomanufacturing.Frontiers in plant science · 2026Review
- Article
- Astragaloside IV promotes the apoptosis of pancreatic cancer cells by activating endoplasmic reticulum stress through the PERK/ATF4/CHOP signaling pathway.Molecular medicine reports · 2026Article
- [Astragaloside IV alleviates D-GAL-induced endothelial cell senescence by promoting mitochondrial autophagyNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- A Pilot EEG Study on the Acute Neurophysiological Effects of Single-Dose Astragaloside IV in Healthy Young Adults.Nutrients · 2025Article
- Astragaloside IV Relieves Mitochondrial Oxidative Stress Damage and Dysfunction in Diabetic Mice Endothelial Progenitor Cells by Regulating the GSK-3β/Nrf2 Axis.Applied biochemistry and biotechnology · 2025Article
- Mechanism of astragaloside A against lung adenocarcinoma based on network pharmacology combined with molecular dynamics simulation technique.Scientific reports · 2025Article
- Total Astragalus saponins promote ferroptosis in gastric cancer cells by upregulating SIRT3.Translational cancer research · 2025Article
- Tailoring traditional Chinese medicine in cancer therapy.Molecular cancer · 2025Review
- Nutritional, Chemical, Antioxidant and Antibacterial Screening ofFoods (Basel, Switzerland) · 2025Article
- Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action.Frontiers in oncology · 2025Review
- Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives.Frontiers in pharmacology · 2025Review
- Astragaloside IV: a potential nemesis for gastric cancer.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.